14 found
Order:
Disambiguations
Matthew S. McCoy [11]Matthew McCoy [2]Matthew Kennedy Mccoy [1]Matthew K. McCoy [1]
  1. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.Ezekiel J. Emanuel, Johan L. Dellgren, Matthew S. McCoy & Govind Persad - forthcoming - New England Journal of Medicine.
    Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, such as tirzepatide, have been found to be effective for treating obesity and diabetes, significantly reducing weight and the risk or predicted risk of adverse cardiovascular events. There is a global shortage of these medications that could last several years and raises questions about how limited supplies should be allocated. We propose a fair-allocation framework that enables evaluation of the ethics of current (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  2.  39
    Ethical Responsibilities for Companies That Process Personal Data.Matthew S. McCoy, Anita L. Allen, Katharina Kopp, Michelle M. Mello, D. J. Patil, Pilar Ossorio, Steven Joffe & Ezekiel J. Emanuel - 2023 - American Journal of Bioethics 23 (11):11-23.
    It has become increasingly difficult for individuals to exercise meaningful control over the personal data they disclose to companies or to understand and track the ways in which that data is exchanged and used. These developments have led to an emerging consensus that existing privacy and data protection laws offer individuals insufficient protections against harms stemming from current data practices. However, an effective and ethically justified way forward remains elusive. To inform policy in this area, we propose the Ethical Data (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   19 citations  
  3. An ethical framework for global vaccine allocation.Ezekiel J. Emanuel, Govind Persad, Adam Kern, Allen E. Buchanan, Cecile Fabre, Daniel Halliday, Joseph Heath, Lisa M. Herzog, R. J. Leland, Ephrem T. Lemango, Florencia Luna, Matthew McCoy, Ole F. Norheim, Trygve Ottersen, G. Owen Schaefer, Kok-Chor Tan, Christopher Heath Wellman, Jonathan Wolff & Henry S. Richardson - 2020 - Science 1:DOI: 10.1126/science.abe2803.
    In this article, we propose the Fair Priority Model for COVID-19 vaccine distribution, and emphasize three fundamental values we believe should be considered when distributing a COVID-19 vaccine among countries: Benefiting people and limiting harm, prioritizing the disadvantaged, and equal moral concern for all individuals. The Priority Model addresses these values by focusing on mitigating three types of harms caused by COVID-19: death and permanent organ damage, indirect health consequences, such as health care system strain and stress, as well as (...)
    Direct download  
     
    Export citation  
     
    Bookmark   12 citations  
  4.  60
    Ethical Advocacy Across the Autism Spectrum: Beyond Partial Representation.Matthew S. McCoy, Emily Y. Liu, Amy S. F. Lutz & Dominic Sisti - 2020 - American Journal of Bioethics 20 (4):13-24.
    Recent debates within the autism advocacy community have raised difficult questions about who can credibly act as a representative of a particular population and what responsibilities that...
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   20 citations  
  5. What are the obligations of pharmaceutical companies in a global health emergency?Ezekiel J. Emanuel, Allen Buchanan, Shuk Ying Chan, Cécile Fabre, Daniel Halliday, Joseph Heath, Lisa Herzog, R. J. Leland, Matthew S. McCoy, Ole F. Norheim, Carla Saenz, G. Owen Schaefer, Kok-Chor Tan, Christopher Heath Wellman, Jonathan Wolff & Govind Persad - 2021 - Lancet 398 (10304):1015.
    All parties involved in researching, developing, manufacturing, and distributing COVID-19 vaccines need guidance on their ethical obligations. We focus on pharmaceutical companies' obligations because their capacities to research, develop, manufacture, and distribute vaccines make them uniquely placed for stemming the pandemic. We argue that an ethical approach to COVID-19 vaccine production and distribution should satisfy four uncontroversial principles: optimising vaccine production, including development, testing, and manufacturing; fair distribution; sustainability; and accountability. All parties' obligations should be coordinated and mutually consistent. For (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  6.  51
    Public involvement in the governance of population-level biomedical research: unresolved questions and future directions.Sonja Erikainen, Phoebe Friesen, Leah Rand, Karin Jongsma, Michael Dunn, Annie Sorbie, Matthew McCoy, Jessica Bell, Michael Burgess, Haidan Chen, Vicky Chico, Sarah Cunningham-Burley, Julie Darbyshire, Rebecca Dawson, Andrew Evans, Nick Fahy, Teresa Finlay, Lucy Frith, Aaron Goldenberg, Lisa Hinton, Nils Hoppe, Nigel Hughes, Barbara Koenig, Sapfo Lignou, Michelle McGowan, Michael Parker, Barbara Prainsack, Mahsa Shabani, Ciara Staunton, Rachel Thompson, Kinga Varnai, Effy Vayena, Oli Williams, Max Williamson, Sarah Chan & Mark Sheehan - 2021 - Journal of Medical Ethics 47 (7):522-525.
    Population-level biomedical research offers new opportunities to improve population health, but also raises new challenges to traditional systems of research governance and ethical oversight. Partly in response to these challenges, various models of public involvement in research are being introduced. Yet, the ways in which public involvement should meet governance challenges are not well understood. We conducted a qualitative study with 36 experts and stakeholders using the World Café method to identify key governance challenges and explore how public involvement can (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  7.  28
    Patient and public involvement: Two sides of the same coin or different coins altogether?Matthew S. McCoy, Jonathan Warsh, Leah Rand, Michael Parker & Mark Sheehan - 2019 - Bioethics 33 (6):708-715.
    Patient and public involvement (PPI) has gained widespread support in health research and health policy circles, but there is little consensus on the precise meaning or justifications of PPI. We argue that an important step towards clarifying the meaning and justification for PPI is to split apart the familiar acronym and draw a distinction between patient and public involvement. Specifically, we argue that patient involvement should refer to the practice of involving individuals in health research or policy on the basis (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  8.  60
    On the Ethics of Vaccine Nationalism: The Case for the Fair Priority for Residents Framework.Ezekiel J. Emanuel, Allen Buchanan, Shuk Ying Chan, Cécile Fabre, Daniel Halliday, R. J. Leland, Florencia Luna, Matthew S. McCoy, Ole F. Norheim, G. Owen Schaefer, Kok-Chor Tan & Christopher Heath Wellman - 2021 - Ethics and International Affairs 35 (4):543-562.
    COVID-19 vaccines are likely to be scarce for years to come. Many countries, from India to the U.K., have demonstrated vaccine nationalism. What are the ethical limits to this vaccine nationalism? Neither extreme nationalism nor extreme cosmopolitanism is ethically justifiable. Instead, we propose the fair priority for residents framework, in which governments can retain COVID-19 vaccine doses for their residents only to the extent that they are needed to maintain a noncrisis level of mortality while they are implementing reasonable public (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  9.  72
    National Standards for Public Involvement in Research: missing the forest for the trees.Matthew S. McCoy, Karin Rolanda Jongsma, Phoebe Friesen, Michael Dunn, Carolyn Plunkett Neuhaus, Leah Rand & Mark Sheehan - 2018 - Journal of Medical Ethics 44 (12):801-804.
    Biomedical research funding bodies across Europe and North America increasingly encourage—and, in some cases, require—investigators to involve members of the public in funded research. Yet there remains a striking lack of clarity about what ‘good’ or ‘successful’ public involvement looks like. In an effort to provide guidance to investigators and research organisations, representatives of several key research funding bodies in the UK recently came together to develop the National Standards for Public Involvement in Research. The Standards have critical implications for (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  10.  39
    Patient‐Engaged Research: Choosing the “Right” Patients to Avoid Pitfalls.Emily A. Largent, Holly Fernandez Lynch & Matthew S. McCoy - 2018 - Hastings Center Report 48 (5):26-34.
    To ensure that the information resulting from research is relevant to patients, the Patient‐Centered Outcomes Research Institute eschews the “traditional health research” paradigm, in which investigators drive all aspects of research, in favor of one in which patients assume the role of research partner. If we accept the premise that patient engagement can offer fresh perspectives that shape research in valuable ways, then at least two important sets of questions present themselves. First, how are patients being engaged—and how should they (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  11.  30
    A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.John H. Brems & Matthew S. McCoy - forthcoming - AJOB Empirical Bioethics:1-7.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  12.  29
    Response to Open Peer Commentaries on “Ethical Responsibilities for Companies That Process Personal Data”.Matthew S. McCoy, Ezekiel J. Emanuel & Steven Joffe - 2024 - American Journal of Bioethics 24 (3):1-5.
    We’re grateful for the thoughtful and incisive commentaries on our article, “Ethical Responsibilities for Companies that Process Personal Data” (McCoy et al. 2023). In the article, we propose the E...
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  13.  28
    Who Is Responsible for Promoting Equity in Rare Disease Research?Matthew S. McCoy - 2023 - American Journal of Bioethics 23 (7):83-85.
    Stories of rare disease advocacy can elicit strong but ambivalent responses. It’s moving to read about the heroic efforts of parents “becoming drug developers to find a cure for their children’s ra...
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  14.  22
    The Cratylus. [REVIEW]Matthew K. McCoy - 1994 - Review of Metaphysics 47 (4):798-799.
    The three stated goals of this book are to provide an interpretation of the Cratylus which determines the roles Hermogenes and Cratylus play in the argument; to do justice to the dialogue's etymologies; and to assess the value of its aporetic conclusions. Baxter succeeds in presenting the dialogue, with its seemingly divergent parts, as a well-constructed whole. Baxter's interpretation enables the reader to raise the same kind of interpretive, philosophical questions that arise when one reads Plato's more accessible dialogues.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark